case report | Q2782326 |
scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1015870782 |
P356 | DOI | 10.1186/S12941-017-0178-0 |
P932 | PMC publication ID | 5240302 |
P698 | PubMed publication ID | 28095918 |
P50 | author | Islam M Ghazi | Q61112484 |
P2093 | author name string | David P Nicolau | |
Mordechai Grupper | |||
P2860 | cites work | Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia. | Q50981341 |
Gentamicin Treatment of Staphylococcal Infections | Q70569146 | ||
Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia | Q33612643 | ||
The postantibiotic effect: a review of in vitro and in vivo data | Q33617455 | ||
Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organisms | Q33694513 | ||
Influence of pulmonary surfactant on in vitro bactericidal activities of amoxicillin, ceftazidime, and tobramycin | Q35111428 | ||
The efficacy and safety of arbekacin and vancomycin for the treatment in skin and soft tissue MRSA infection: preliminary study | Q37192126 | ||
In vitro models for the study of antibiotic activities | Q39694601 | ||
Prospective randomized clinical trial of teicoplanin for empiric combined antibiotic therapy in febrile, granulocytopenic acute leukemia patients. | Q39828435 | ||
Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia | Q40675239 | ||
Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem | Q40913492 | ||
Effect of pulmonary surfactant on antimicrobial activity in vitro | Q42049487 | ||
Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant Staphylococcus aureus collected from US hospitals | Q42204946 | ||
In Vitro Antibacterial Activity of Amikacin, a New Aminoglycoside, Against Clinical Bacterial Isolates from Children | Q43590856 | ||
Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact | Q46494181 | ||
Pulmonary Drug Delivery System for inhalation therapy in mechanically ventilated patients. | Q46839239 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | amikacin | Q408529 |
drug delivery | Q1392806 | ||
infectious disease | Q18123741 | ||
P304 | page(s) | 2 | |
P577 | publication date | 2017-01-17 | |
P1433 | published in | Annals of Clinical Microbiology and Antimicrobials | Q15765734 |
P1476 | title | Anti-staphylococcal activity resulting from epithelial lining fluid (ELF) concentrations of amikacin inhale administered via the pulmonary drug delivery system | |
P478 | volume | 16 |
Search more.